Is this your firm? Get featured or correct your listing →
At a glance
Eli Lilly and Company appears in 3 funding rounds tracked by ValueAddVC since 2026. Its most frequent sector in these rounds is Health & Biotech, and its most recent tracked deal was General Medicine's $120M Series B round (Oct 6, 2026). It co-invests most often with Andreessen Horowitz.
Strategy
Recent changes
- Oct 6, 2026Oct 6, 2026Invested in General Medicine (Series B, $120M) PR Newswire
- Sep 24, 2026Sep 24, 2026Invested in BigHat Biosciences (Series C, $75M) BioSpace
- Sep 8, 2026Sep 8, 2026Invested in Moonwalk Biosciences (Series B, $70M) BioSpace
Portfolio
4 totalRecent Investment Activity
3Track record: led 0 and participated in 3 of 3 tracked venture rounds · 3 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | General Medicine | Series B | Participated | $120M | — | Andreessen HorowitzLeadunverifiedMatrix PartnersunverifiedEli Lilly and CompanyunverifiedBoxGroupunverifiedVXI CapitalMercy Health | PR Newswire |
| Sep 24, 2026 | BigHat Biosciences | Series C | Participated | $75M | — | DFJ GrowthLeadPremji InvestLeadCatalio Capital ManagementLG Technology Ventures8VCAndreessen HorowitzEli Lilly and CompanyMerck Global Health Innovation FundQuadrille CapitalGRIDS CapitalIntermountain VenturesSection 32Sigmas GroupAmgen VenturesAlexandria Venture InvestmentsDiscovery Ventures | BioSpace |
| Sep 8, 2026 | Moonwalk Biosciences | Series B | Participated | $70M | — | BioSpace |
Sector / Stage Activity
Co-Investors
12Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Oct 12, 2026Forbion Closes Record $2.6B Across Two FundsLife sciences investor Forbion closed €2.3 billion ($2.6 billion) across two new funds, its largest fundraise in 20 years, lifting total assets under management to about €7.5 billion.→
- Oct 6, 2026General Medicine Raises $120M to Build a 'Healthcare Store'General Medicine raised a $120 million Series B led by Andreessen Horowitz to expand its platform letting patients search, compare and buy healthcare services with transparent pricing.→
- Sep 15, 2026Thatch Hits Unicorn Status As Health Costs SurgeThatch, an ICHRA marketplace that lets employers fund individual health plans instead of one group policy, raised a $108 million Series C at a $1 billion valuation as revenue grew nearly sevenfold over the past year.→
- Sep 8, 2026Moonwalk Biosciences Raises $70M For Obesity RNAiMoonwalk Biosciences closed an oversubscribed $70 million Series B to advance an adipose-targeted RNA interference therapy for obesity toward its first human trial, bringing total funding to roughly $127 million since its 2024 launch.→
- Sep 3, 2026Superluminal Raises $60M for AI-Designed Obesity PillThe Boston biotech's Series B, backed by Nvidia and Eli Lilly among others, funds Phase 1 trials of an oral MC4R agonist for rare genetic obesity designed by its de novo drug-discovery AI platform.→
- Jul 17, 2026Chai Discovery Raises $400M at $3.8B for AI Drug DesignLife-sciences AI startup Chai Discovery raised a $400 million Series C at a $3.8 billion valuation led by Index Ventures, with Sequoia, Dimension and Kleiner Perkins participating, one of the largest rounds yet for AI-driven drug and molecule design.→
- Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→
Eli Lilly and Company FAQ
What companies has Eli Lilly and Company invested in?
Eli Lilly and Company's portfolio includes General Medicine, BigHat Biosciences, Moonwalk Biosciences, Flare Therapeutics.
Who does Eli Lilly and Company co-invest with most?
In the rounds Value Add tracks, Eli Lilly and Company most often invests alongside Andreessen Horowitz (2 shared deals), 8VC (1 shared deal), Alpha Wave Global (1 shared deal), ARCH Venture Partners (1 shared deal), Boxer Capital (1 shared deal).
Sources & methodologyshow
- PR Newswireprimary source1 fact
- BioSpaceresearch database1 fact
- BioSpaceresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.